A new study conducted by the Wilhelm Lab at the University of Oklahoma examines a promising development in biomedical ...

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

A new vaccine for dengue received prequalification from the World Health Organization (WHO) on 10 May 2024. TAK-003 is the ...

These vaccines, jointly developed by pharma giants Moderna and Merck, have been shown in trials conducted so far to be significantly more effective in combination with immunotherapy than immunotherapy ...

Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be ...

Pharmaceutical firm Moderna Japan is aiming to start clinical trials this winter for a combined vaccine using messenger RNA ...

Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational ...

Small clinical trials have shown the individually tailored mRNA vaccines can produce a very rapid immune system response.

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial ...

We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

Moderna shares fell in intraday trading Friday as it said the FDA has pushed back its RSV vaccine approval decision until the ...